Co-Authors
                            
                            
                                This is a "connection" page, showing publications co-authored by   Douglas Corley   and   Lawrence Kushi.
                            
                            
                            
                                
                                    
                                            
    
        
        
        
            Connection Strength
            
                
            
            0.878
         
        
        
     
 
    
        
        - 
            Risk of severe clinical outcomes among persons with SARS-CoV-2 infection with differing levels of vaccination during widespread Omicron (B.1.1.529) and Delta (B.1.617.2) variant circulation in Northern California: A retrospective cohort study. Lancet Reg Health Am. 2022 Aug; 12:100297.
            
            
                Score: 0.200
            
         
        
        - 
            Primary care visit use after positive fecal immunochemical test for colorectal cancer screening. Cancer. 2017 Oct 01; 123(19):3744-3753.
            
            
                Score: 0.142
            
         
        
        - 
            Unraveling the genetic landscape of susceptibility to multiple primary cancers. HGG Adv. 2025 Apr 10; 6(2):100413.
            
            
                Score: 0.060
            
         
        
        - 
            Unraveling the genetic landscape of susceptibility to multiple primary cancers. medRxiv. 2024 Oct 30.
            
            
                Score: 0.059
            
         
        
        - 
            Relative contribution of COVID-19 vaccination and SARS-CoV-2 infection to population-level seroprevalence of SARS-CoV-2 spike antibodies in a large integrated health system. PLoS One. 2024; 19(6):e0303303.
            
            
                Score: 0.058
            
         
        
        - 
            Relative contribution of COVID-19 vaccination and SARS-CoV-2 infection to population-level seroprevalence of SARS-CoV-2 spike antibodies in a large integrated health system. medRxiv. 2024 Feb 02.
            
            
                Score: 0.056
            
         
        
        - 
            Assessment of genetic susceptibility to multiple primary cancers through whole-exome sequencing in two large multi-ancestry studies. BMC Med. 2022 10 06; 20(1):332.
            
            
                Score: 0.051
            
         
        
        - 
            Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies. Open Forum Infect Dis. 2022 Jun; 9(6):ofac171.
            
            
                Score: 0.050
            
         
        
        - 
            Cross-cancer evaluation of polygenic risk scores for 16 cancer types in two large cohorts. Nat Commun. 2021 02 12; 12(1):970.
            
            
                Score: 0.046
            
         
        
        - 
            Pan-cancer study detects genetic risk variants and shared genetic basis in two large cohorts. Nat Commun. 2020 09 04; 11(1):4423.
            
            
                Score: 0.044
            
         
        
        - 
            Clinical Molecular Marker Testing Data Capture to Promote Precision Medicine Research Within the Cancer Research Network. JCO Clin Cancer Inform. 2019 09; 3:1-10.
            
            
                Score: 0.041
            
         
        
        - 
            Collaborating on Data, Science, and Infrastructure: The 20-Year Journey of the Cancer Research Network. EGEMS (Wash DC). 2019 Mar 29; 7(1):7.
            
            
                Score: 0.040
            
         
        
        - 
            Imputation of the rare HOXB13 G84E mutation and cancer risk in a large population-based cohort. PLoS Genet. 2015 Jan; 11(1):e1004930.
            
            
                Score: 0.030